Higuchi 0 0 Kinetik


15. Travis W NS, Hirsch FR, Pugatch B, Geisinger K, Brambilla E, Gazdar A, Petersen I, Meyerson M, Hanash SM, Jen J, Takahashi T, Fernandez EA, Capron F. Small cell carcinoma. In: Travis WD BE, Müller-Hermelink HK, Harris CC, editor. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARCPress; 2004. p. 31-4.

16. Hammar SP BC, Pugatch B, Geisinger K, Fernandez EA, Vogt P, Petrovitchev N, Matsuno Y, Aisner S, Rami-Porta R, Capelozzi VL, Schmidt R, Carvalho L, Petersen I, Gazdar A, Meyerson M, Hanash SM, Jen J, Harris CC. Squamous cell carcinoma. In: Travis W BE, Müller-Hermelink HK, Harris CC, editor.

Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart.

Lyon: IARCPress; 2004. p. 26-30.

17. Colby TV NM, Henschke C, Vazquez MF, Geisinger K, Yokose T, Ohori P, Rami-Porta R, Franks T, Shimosato Y, Matsuno Y, Khoor A, Westra WH, Jambhekar NA, Petersen I, Takahashi T, Kawai T, Meyerson M, Hanash SM, Jen J. Adenocarcinoma. In: Travis W BE, Müller-Hermelink HK, Harris CC, editor. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004. p. 35-44.

18. Brambilla E PB, Geisinger K, Gal A, Sheppard MN, Guinee DG, Jiang SX, Lantuejoul S, Chang YL, Petersen I, Meyerson M, Hanash SM, Noguchi M.

Large cell carcinoma. In: Travis W BE, Müller-Hermelink HK, Harris CC, editor. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004. p. 45-50.

19. De Wever W, Verschakelen J, Coolen J. Role of imaging in diagnosis, staging and follow-up of lung cancer. Curr Opin Pulm Med. 2014;20(4):385-92.

20. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer:

Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e142S-e65S.

21. Necdet Poyraz KÖ. Akciğer Kanserinin Tanı ve Takibinde Radyolojik Görüntüleme. Turkiye Klinikleri Thoracic Surgery. 2017;8:57-66.

22. Hyer JD, Silvestri G. Diagnosis and staging of lung cancer. Clin Chest Med.

2000;21(1):95-106, viii-ix.

23. Hollings N, Shaw P. Diagnostic imaging of lung cancer. Eur Respir J.


24. Hayashi H, Ashizawa K, Uetani M, Futagawa S, Fukushima A, Minami K, ve ark. Detectability of peripheral lung cancer on chest radiographs: effect of the size, location and extent of ground-glass opacity. Br J Radiol.


25. MacMahon H, Li F, Engelmann R, Roberts R, Armato S. Dual energy subtraction and temporal subtraction chest radiography. J Thorac Imag.


26. Kim SM, Chung MJ, Lee KS, Kang H, Song IY, Lee EJ, ve ark. Digital tomosynthesis of the thorax: the influence of respiratory motion artifacts on lung nodule detection. Acta Radiol. 2013;54(6):634-9.

27. Quaia E, Baratella E, Poillucci G, Kus S, Cioffi V, Cova MA. Digital Tomosynthesis as a Problem-Solving Imaging Technique to Confirm or Exclude Potential Thoracic Lesions Based on Chest X-Ray Radiography. Acad Radiol. 2013;20(5):546-53.

28. Xiang D, Zhang B, Doll D, Shen K, Kloecker G, Freter C. Lung cancer screening: from imaging to biomarker. Biomark Res. 2013;1(1):4.

29. Sone S, Li F, Yang ZG, Honda T, Maruyama Y, Takashima S, ve ark. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Brit J Cancer. 2001;84(1):25-32.

30. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, ve ark. CT screening for lung cancer: Five-year prospective experience.

Radiology. 2005;235(1):259-65.

31. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, ve ark. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New Engl J Med. 2011;365(5):395-409.

32. Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, ve ark.

Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(4):412-41.

33. Walsh SL, Nair A, Hansell DM. Post-processing applications in thoracic computed tomography. Clin Radiol. 2013;68(5):433-48.

34. Zhang LJ, Yang GF, Wu SY, Xu J, Lu GM, Schoepf UJ. Dual-energy CT imaging of thoracic malignancies. Cancer Imaging. 2013;13(1):81-91.

35. Vardhanabhuti V, Loader RJ, Mitchell GR, Riordan RD, Roobottom CA. Image Quality Assessment of Standard- and Low-Dose Chest CT Using Filtered Back Projection, Adaptive Statistical Iterative Reconstruction, and Novel Model-Based Iterative Reconstruction Algorithms. Am J Roentgenol.


36. Revel MP, Merlin A, Peyrard S, Triki R, Couchon S, Chatellier G, ve ark.

Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. Am J Roentgenol. 2006;187(1):135-42.

37. Ma SH, Le HB, Jia BH, Wang ZX, Xiao ZW, Cheng XL, ve ark. Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer.


38. Lee WK, Lau EW, Chin K, Sedlaczek O, Steinke K. Modern diagnostic and therapeutic interventional radiology in lung cancer. J Thorac Dis. 2013;5 Suppl 5:S511-23.

39. Armato SG, 3rd, Labby ZE, Coolen J, Klabatsa A, Feigen M, Persigehl T, ve ark. Imaging in pleural mesothelioma: a review of the 11th International

Conference of the International Mesothelioma Interest Group. Lung Cancer.


40. Sommer G, Tremper J, Koenigkam-Santos M, Delorme S, Becker N, Biederer J, ve ark. Lung nodule detection in a high-risk population: comparison of magnetic resonance imaging and low-dose computed tomography. Eur J Radiol.


41. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC.

Surgical treatment of primary lung cancer with synchronous brain metastases.

J Thorac Cardiov Sur. 2001;122(3):548-53.

42. Yi CA, Shin KM, Lee KS, Kim BT, Kim H, Kwon OJ, ve ark. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248(2):632-42.

43. Hatabu H, Stock KW, Sher S, Edinburgh KJ, Levin DL, Garpestad E, ve ark.

Magnetic resonance imaging of the thorax. Past, present, and future. Clin Chest Med. 1999;20(4):775-803, viii-ix.

44. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med. 1996;37(6):943-8.

45. Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman E, Wolfe WG.

Lung-Tumor Growth Correlates with Glucose-Metabolism Measured by Fluoride-18 Fluorodeoxyglucose Positron Emission Tomography. Ann Thorac Surg. 1995;60(5):1348-52.

46. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, ve ark.

Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol. 1998;16(3):1075-84.

47. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions - A meta-analysis. Jama-J Am Med Assoc. 2001;285(7):914-24.

48. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM, Onko PETdDGfN.

[Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000]. Pneumologie.


49. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta-analytic comparison of PET and CT. Radiology. 1999;213(2):530-6.

50. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, ve ark. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol.


51. He YQ, Gong HL, Deng YF, Li WM. Diagnostic efficacy of PETand PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol. 2014;55(3):309-17.

52. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, ve ark. Positron emission tomography is superior to computed tomography

scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol.


53. Sobic-Saranovic D, Pavlovic S, Jovanovic D, Neboisa K, Todorovic-Timanic M, Subotic D, et al. Assessment of non-small cell lung cancer viability and necrosis with three radiopharmaceuticals. Hell J Nucl Med. 2008;11(1):16-20.

54. Spanu A, Schillaci O, Pirina P, Arru A, Madeddu G, Chessa F, ve ark. 99mTc-tetrofosmin SPECT in solitary pulmonary nodule evaluation. Oncol Rep.


55. Wang L, Yin X, Wang F, Gu J, Lu L, Wu Q, et al. The usefulness of combined diagnostic CT and (99m)Tc-octreotide somatostatin receptor SPECT/CT imaging on pulmonary nodule characterization in patients. Cancer Biother Radiopharm. 2013;28(10):731-6.

56. Nishiyama Y, Yamamoto Y, Satoh K, Ohkawa M, Kameyama K, Hayashi E, et al. Comparative study of Tc-99m MIBI and TI-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin Nucl Med.


57. Hammerschmidt S, Wirtz H. Lung cancer: current diagnosis and treatment.

Dtsch Arztebl Int. 2009;106(49):809-18; quiz 19-20.

58. Lackey A, Donington JS. Surgical management of lung cancer. Semin Intervent Radiol. 2013;30(2):133-40.

59. Hennon MW, Demmy TL. Video-assisted thoracoscopic surgery (VATS) for locally advanced lung cancer. Ann Cardiothorac Surg. 2012;1(1):37-42.

60. Wei S, Chen M, Chen N, Liu L. Feasibility and safety of robot-assisted thoracic surgery for lung lobectomy in patients with non-small cell lung cancer: a systematic review and meta-analysis. World J Surg Oncol. 2017;15(1):98.

61. Parashar B, Arora S, Wernicke AG. Radiation therapy for early stage lung cancer. Semin Intervent Radiol. 2013;30(2):185-90.

62. Dinçbaş FÖ. Akciğer Kanserinde Radyoterapi. Sempozyum Dizisi.


63. Davis JN, Medbery C, Sharma S, Pablo J, Kimsey F, Perry D, ve ark.

Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch((R)) patient registry. Radiat Oncol. 2015;10:113.

64. Skowronek J. Brachytherapy in the treatment of lung cancer - a valuable solution. J Contemp Brachytherapy. 2015;7(4):297-311.

65. Goldberg M, Timotin E, Farrell T, Puksa S, Donde B, Sur R. A prospective analysis of high-dose-rate endobronchial brachytherapy in the palliation of obstructive symptoms in lung cancer patients: A single-institution experience.

Brachytherapy. 2015;14(5):655-61.

66. Huo X, Wang H, Yang J, Li X, Yan W, Huo B, et al. Effectiveness and safety of CT-guided (125)I seed brachytherapy for postoperative locoregional

recurrence in patients with non-small cell lung cancer. Brachytherapy.


67. Yamamoto T, Kabus S, Bal M, Keall P, Benedict S, Daly M. The first patient treatment of computed tomography ventilation functional image-guided radiotherapy for lung cancer. Radiother Oncol. 2016;118(2):227-31.

68. Baisi A, De Simone M, Raveglia F, Cioffi U. Thermal ablation in the treatment of lung cancer: present and future. Eur J Cardiothorac Surg. 2013;43(4):683-6.

69. Sidoff L, Dupuy DE. Clinical experiences with microwave thermal ablation of lung malignancies. Int J Hyperthermia. 2017;33(1):25-33.

70. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000;174(1):57-9.

71. Narsule CK, Sridhar P, Nair D, Gupta A, Oommen RG, Ebright MI, et al.

Percutaneous thermal ablation for stage IA non-small cell lung cancer: long-term follow-up. J Thorac Dis. 2017;9(10):4039-45.

72. de Baere T, Auperin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, et al.

Radiofrequency ablation is a valid treatment option for lung metastases:

experience in 566 patients with 1037 metastases. Ann Oncol. 2015;26(5):987-91.

73. De Baère T, Mahnken, A.H. Radiofrequency Ablation for Treating Malignant Tumors to the Lungs. In: Eric Van Cutsem EVC, Alberto Sobrero, editor.

Locoregional Tumor Therapy. Switzerland: Springer International Publishing AG; 2018. p. 235-42.

74. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25 Suppl 1:S69-83.

75. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, ve ark.

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005;23(28):6854-64.

76. Timmer-Bonte JN, Punt CJ, vd Heijden HF, van Die CE, Bussink J, Beijnen JH, ve ark. Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung Cancer.


77. Pirker R. EGFR-directed monoclonal antibodies in non-small cell lung cancer.

Target Oncol. 2013;8(1):47-53.

78. Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, ve ark.

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997-2003.

79. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, ve ark. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259-67.

80. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, ve ark. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res.


81. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, ve ark.

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927-36.

82. Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology. 2013;2(5):e24436.

83. Cui J, Cai X, Zhu M, Liu T, Zhao N. The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials. PLoS One. 2013;8(4):e62038.

84. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, ve ark.

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol.


85. Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, ve ark.

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol.


86. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, ve ark. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

N Engl J Med. 2012;366(26):2443-54.

87. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, ve ark. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31(19):2396-403.

88. Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, Nyakas M, ve ark.

Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.

Clin Cancer Res. 2011;17(21):6847-57.

89. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, ve ark. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010;59(10):1467-79.

90. Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, ve ark.

CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. Expert Opin Biol Ther. 2018;18(7):829-35.

91. Skrzypski M, Jassem J. Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treat Rev. 2018;66:114-21.

92. Freeman-Keller M, Goldman J, Gray J. Vaccine immunotherapy in lung cancer:

Clinical experience and future directions. Pharmacol Ther. 2015;153:1-9.

93. Kelly RJ, Giaccone G. Lung cancer vaccines. Cancer J. 2011;17(5):302-8.

94. Lievense LA, J.; Hegmans, J. Immune Therapy. In: Ahmad AG, S., editor. Lung Cancer and Personalized Medicine Current Knowledge and Therapies.

Switzerland: Sipringer; 2016. p. 59- 83.

95. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-94.

96. Cafarotti SL, F.; Froesh, P.; Zappa, F; Andrè, D. Target Therapy in Lung Cancer. In: Ahmad AG, S. , editor. Lung Cancer and Personalized Medicine Current Knowledge and Therapies. Switzerland: Springer International Publishing; 2016. p. 127- 36.

97. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, ve ark. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018;13(3):323-58.

98. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, ve ark.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

N Engl J Med. 2010;362(25):2380-8.

99. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, ve ark. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32.

100. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, ve ark. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527-37.

101. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, ve ark. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-22.

102. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, ve ark. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577-89.

103. Edwards RL, Andan C, Lalla RV, Lacouture ME, O'Brien D, Sequist LV.

Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment. Clin J Oncol Nurs.


104. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, ve ark. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-25.

105. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, ve ark.

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

N Engl J Med. 2017;376(7):629-40.

106. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, ve ark. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer. 2014;83(2):211-8.

107. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, ve ark.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50.

108. Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, ve ark.

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer. 2012;76(3):362-7.

109. Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, ve ark. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33(19):2197-204.

110. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, ve ark.

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol.


111. Ellis PM. Anti-angiogenesis in Personalized Therapy of Lung Cancer. In:

Aamir Ahmad SG, editor. Lung Cancer and Personalized Medicine Current Knowledge and Therapies. Switzerland: Springer International Publishing 2016. p. 91- 126.

112. Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, ve ark. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015;121(6):883-92.

113. Kim ES. Chemotherapy Resistance in Lung Cancer. In: Aamir Ahmad SG, editor. Lung Cancer and Personalized Medicine Current Knowledge and Therapies. Advances in Experimental Medicine and Biology. Springer International Publishing AG Switzerland: Springer; 2016. p. 189- 209.

114. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311(7010):899-909.

115. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, ve ark. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016-24.

116. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, ve ark.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-8.

117. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999;91(1):66-72.

118. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, ve ark.

Chemotherapy for elderly patients with advanced non-small-cell lung cancer:

the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95(5):362-72.

119. Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int.


120. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994;5 Suppl 6:S3-6.

121. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8.

122. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother. 1994;28(5 Suppl):S11-4.

123. Mastropaolo D, Camerman A, Luo Y, Brayer GD, Camerman N. Crystal and molecular structure of paclitaxel (taxol). Proc Natl Acad Sci U S A.


124. Faller BA, Pandit TN. Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. Clin Med Insights Oncol. 2011;5:131-44.

125. Leveque D, Jehl F. Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet. 1996;31(3):184-97.

126. Jung M, Grunberg S, Timblin C, Buder-Hoffman S, Vacek P, Taatjes DJ, ve ark. Paclitaxel and vinorelbine cause synergistic increases in apoptosis but not in microtubular disruption in human lung adenocarcinoma cells (A-549).

Histochem Cell Biol. 2004;121(2):115-21.

127. Huerter MM, Meza JL, Copur MS, Tolentino A, Marr AS, Ketcham M, ve ark.

Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study. J Geriatr Oncol. 2017;8(1):18-22.

128. Lilenbaum RC, Herndon JE, 2nd, List MA, Desch C, Watson DM, Miller AA, ve ark. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol.